Abstract
Purpose Treatment options for sJIA are limited. Excessive IL-6 production has been implicated in several manifestations of this disease. In a previous Japanese study, TCZ, an IL-6 receptor inhibitor, improved arthritis and systemic features of patients with refractory sJIA. We present efficacy and safety of TCZ in patients with active sJIA who were treated for ≥52 wks in the global, 3-part, 5-yr, phase 3, multicenter TENDER study. Methods
Highlights
systemic juvenile idiopathic arthritis (SJIA) refractory to immunosuppressants including methotrexate and TNF-a inhibitors can lead to severe disabilities
Background sJIA refractory to immunosuppressants including methotrexate and TNF-a inhibitors can lead to severe disabilities
Excessive IL-6 production has been implicated in the pathoetiology of sJIA
Summary
SJIA refractory to immunosuppressants including methotrexate and TNF-a inhibitors can lead to severe disabilities. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data Background sJIA refractory to immunosuppressants including methotrexate and TNF-a inhibitors can lead to severe disabilities. Aim To determine the efficacy and safety of TCZ, an IL-6 receptor inhibitor, in patients (pts) with sJIA treated for 52 weeks (wks) in the ongoing, 3-part, 5-year, phase 3 TENDER study.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
